HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mandatory AE Information Requirements Needed For CAERS Filings – AHPA

This article was originally published in The Tan Sheet

Executive Summary

Adverse event reports should be required to contain certain information before being filed in the CFSAN Adverse Events Reporting System (CAERS), AHPA says in an Oct. 21 letter to the agency

You may also be interested in...

Mandatory Supplement AE Reporting Possible Under Current Law – AHPA

FDA has the authority to require mandatory adverse event reporting for dietary supplements under current law, the American Herbal Products Association maintains in a recent citizen petition

NVE Ephedra AERs Total 40; Yellow Jacket Distribution Halted

NVE Pharmaceuticals has received only 40 adverse event reports related to its ephedra-containing dietary supplements, the firm tells Sen. Richard Durbin (D-Ill.) in an Oct. 21 letter

CFSAN Adverse Event Strategy: Will Notifying Industry Create A 2-Way Road?

CFSAN will begin sending letters to companies notifying them when an adverse event report involving one of their products has been received on or after Sept. 16

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts